Diabetic macular edema

Disease2 papers1 finding

Humans1

Associations

1

SGLT2 inhibitors

downin humans1HR 0.65–0.84Moderate certainty

1 study

SGLT2 inhibitors lower the risk of diabetic macular edema in humans (16%-35% lower (HR 0.65-0.84)).
Review
Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage-Dependent Systemic-Retinal Responsiveness · Diabetes, obesity & metabolism · 2 Sep 2026

SGLT2 inhibitors →

Trial sponsors

Allergan
Company4 trialsPhase 31,357 people
Oculis
Company2 trialsPhase 3953 people
EyePoint Pharmaceuticals
Company2 trialsPhase 3480 people
Santen
Company2 trialsPhase 2181 people
EnnovaBio
Company1 trialPhase 260 people
Sanwa Kagaku Kenkyusho
Company1 trialPhase 1/2
The Cleveland Clinic
1 trialPhase 430 people
Retina Macula Specialists of Miami
1 trialPhase 420 people

Latest

2

Diabetes, Obesity & MetabolismReview3 Sep

Sodium-Glucose Cotransporter 2 Inhibition in Diabetic Macular Oedema: Emerging Evidence for Stage-Dependent Systemic-Retinal Responsiveness

SGLT2 inhibitors

Diabetes, Obesity & MetabolismHumans28 Aug

Association of GLP1-Receptor Agonists With Diabetic Retinopathy

GLP-1 receptor agonists